A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff (BLAZE-2)
The purpose of this study is to evaluate whether LY3819253 given alone and with LY3832479 prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease – 2019 (COVID-19) in facility staff and residents in skilled nursing and assisted living facilities with a high risk of SARS-CoV-2 exposure. Participants with a high risk of SARS-CoV-2 exposure will receive LY3819253, LY3819253 and LY3832479, or placebo via an injection into a vein. Samples will be taken from the nose. Blood samples will be drawn. To speak with a study representative, call 718-210-9713.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants must either live or work in a nursing home that has at least one confirmed case of COVID-19 with the last week
Participants must agree to the collection of several blood samples and swab samples from the nose
Participants must have venous access sufficient to allow intravenous infusions and blood sampling
Participant or legally authorized representative must give signed informed consent
Participants must agree to approved birth control to prevent pregnancy
Participants Must Not:
Participants must not be in the hospital
Participants must not be pregnant or breastfeeding
Lilly Trial Alerts
You will complete the questionnaire on another website.YesNo